This study will evaluate the safety and effectiveness of baricitinib in the treatment of
giant cell arteritis. All participants will be taking prednisone at the start of the study.
The prednisone will be reduced according to a standardized tapering schedule while
participants continue to take one tablet of baricitinib daily for 52 weeks.